Actinogen Medical Limited, a biotechnology company, develops treatments for Alzheimer’s disease, and the cognitive deficiency associated with other neurological and metabolic diseases in Australia.
The last earnings update was 46 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Actinogen Medical. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Actinogen Medical's earnings available for a low price, and how does
this compare to other companies in the same industry?
Actinogen Medical is not considered high growth as it is expected to be loss making for the next 1-3 years.
Actinogen Medical's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Actinogen Medical's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Actinogen Medical's finances.
The net worth of a company is the difference between its assets and liabilities.
Actinogen Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Actinogen Medical's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Actinogen Medical's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is not covered by short term assets, assets are -1.6650092449885E+17x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. John William Ketelbey, also known as Bill, MBBCH, FFPM, MBA, GAICD, has been the Chief Executive Officer and Managing Director at Actinogen Medical Limited since December 18, 2014. Dr. Ketelbey is responsible for overseeing the development and commercialisation of XanamemTM for the treatment of Alzheimer's disease and mild cognitive impairment. Dr. Ketelbey has specialist expertise in pharmaceutical medicine including in particular experience in neurological drugs. At Pfizer, Dr. Ketelbey was In Charge of the Australian/New Zealand development and involved in the launch and commercialisation of AriceptTM (donepezil), an acetylcholinesterase inhibitor, the market leading Alzheimer's disease therapy locally and globally. He was involved in developing monoclonal antibodies directed at amyloid plaques, a hallmark of Alzheimer's. Dr. Ketelbey served as Regional Vice President of Medical Affairs for Pfizer's Primary Care Business Unit for Australia and New Zealand, Japan, Canada, Korea and Country Medical Director for Pfizer Australia and New Zealand. Dr. Ketelbey serves as a Director of Actinogen Medical Limited. Dr. Ketelbey is a highly experienced and successful healthcare and pharmaceutical sector professional, with 30 years' experience in the industry, including senior medical and management roles with global pharmaceutical giant, Pfizer. Dr. Ketelbey is a qualified Medical Doctor from the University of the Witwatersrand, South Africa and an MBA graduate from Macquarie University.
Bill's compensation has increased whilst company is loss making.
Bill's remuneration is lower than average for companies of similar size in Germany.
MD, CEO & Director
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Actinogen Medical board of directors is about average.
Board of Directors
MD, CEO & Director
Chairman of Xanamem Clinical Advisory Board
Member of Xanamem Clinical Advisory Board
Member of Xanamem Clinical Advisory Board
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Actinogen Medical Limited, a biotechnology company, develops treatments for Alzheimer’s disease, and the cognitive deficiency associated with other neurological and metabolic diseases in Australia. It is developing Xanamem, a therapy for Alzheimer’s disease; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild dementia due to Alzheimer’s disease. The company is also developing XanaHES, a Phase I, single blinded, central reader blinded, placebo-controlled, dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited is based in Sydney, Australia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.